Avaxia wins Phase II SBIR grant to develop inflammatory bowel disease therapy
The grant, which provides $1.5m in funding over two years, was based on the successful completion of a Phase I SBIR award. Avaxia founder and CEO Barbara Fox
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
Calibr is an independent, not-for-profit organization established to offer academic scientists an efficient and flexible path for translating their biomedical research into novel medicines. Calibr investigators will advance